| pubmed-article:12671693 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12671693 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12671693 | lifeskim:mentions | umls-concept:C0034380 | lld:lifeskim |
| pubmed-article:12671693 | lifeskim:mentions | umls-concept:C0012634 | lld:lifeskim |
| pubmed-article:12671693 | lifeskim:mentions | umls-concept:C0205282 | lld:lifeskim |
| pubmed-article:12671693 | lifeskim:mentions | umls-concept:C0357131 | lld:lifeskim |
| pubmed-article:12671693 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:12671693 | pubmed:dateCreated | 2003-4-2 | lld:pubmed |
| pubmed-article:12671693 | pubmed:abstractText | This open-label, prospective study was conducted to compare the impact of epoetin beta vs standard care on quality of life (QoL) in anaemic patients with lymphoid or solid tumour malignancies. A total of 262 anaemic patients (haemoglobin [Hb]<or=11 g dl(-1)) were randomised to a 12-week treatment with s.c. epoetin beta (initial dose 150 IU kg(-1) three times weekly) or standard care. Transfusions were recommended for both groups at an Hb threshold of 8.5 g dl(-1). The primary efficacy variables were improvement in QoL as measured using the Short-Form-36 physical component summary (SF-36 PCS) score and the Functional Assessment of Cancer Therapy fatigue and anaemia subscales (FACT-F and FACT-An). A visual analogue scale (VAS) was also used as a global QoL measure. Clinical response was defined as a >or=2 g dl(-1) increase in Hb level without need of transfusion after the initial 4 weeks of treatment. Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin beta than with standard care (P<0.05); changes in FACT-An subscale score tended to be greater with epoetin beta (P=0.076). Epoetin beta significantly increased Hb concentrations relative to standard care (responders: 47% vs 13%; P<0.001). Levels of endogenous erythropoietin <50 mIU ml(-1) were significantly predictive of response (OR 2.496, 95% CI: 1.21-5.13). Epoetin beta therapy significantly improves QoL compared with standard care in anaemic patients with solid tumours and lymphoid malignancies. | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12671693 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12671693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12671693 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12671693 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:12671693 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:12671693 | pubmed:author | pubmed-author:CoiffierBB | lld:pubmed |
| pubmed-article:12671693 | pubmed:author | pubmed-author:BoogaertsMM | lld:pubmed |
| pubmed-article:12671693 | pubmed:author | pubmed-author:KainzCC | lld:pubmed |
| pubmed-article:12671693 | pubmed:author | pubmed-author:Epoetin... | lld:pubmed |
| pubmed-article:12671693 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12671693 | pubmed:day | 7 | lld:pubmed |
| pubmed-article:12671693 | pubmed:volume | 88 | lld:pubmed |
| pubmed-article:12671693 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12671693 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12671693 | pubmed:pagination | 988-95 | lld:pubmed |
| pubmed-article:12671693 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:meshHeading | pubmed-meshheading:12671693... | lld:pubmed |
| pubmed-article:12671693 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12671693 | pubmed:articleTitle | Impact of epoetin beta on quality of life in patients with malignant disease. | lld:pubmed |
| pubmed-article:12671693 | pubmed:affiliation | Labo Hematologie Transplant, U.Z. Gasthuisberg, Leuven, Belgium. Marc.Boogaerts@med.kuleuven.ac.be | lld:pubmed |
| pubmed-article:12671693 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12671693 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12671693 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:12671693 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12671693 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12671693 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12671693 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12671693 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12671693 | lld:pubmed |
